Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive CMV-specific T Cells in Haploidentical HSCT
NCT02985775Phase 2Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2017
- Primary completion
- Mar 2018
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytomegalovirus pp65-specific cytotoxic T lymphocytes in cytomegalovirus infection (CMV), sponsored by Peking University People's Hospital. Primary endpoints: Virologic efficacy of CMVpp65-specific T cells for prophylaxis against refractory CMV infection at 6 months and Number of participants with treatment-related adverse events at 6 months. Started Jan 2017; status: completed.
02
Drugs
cytomegalovirus pp65-specific cytotoxic T lymphocytes
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02985775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985775.